Carotid intima-media thickness as a predictor of response to cholinesterase inhibitors in Alzheimer's disease: An open-label trial

CNS Drugs

Volumn 23, Issue 3, 2009, Pages 253-260

  Modrego, Pedro J ^a   Rios, Consuelo ^b   Pérez Trullen, José M ^c   García Gómara, Maria J ^c   Errea, José M ^b,d  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b HOSPITAL DE BARBASTRO   (Spain)

^c Hospital Ernest Lluch De Calatayud   (Spain)

^d HOSPITAL ROYO VILLANOVA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTERIAL WALL THICKNESS; ARTICLE; CAROTID ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORRELATION COEFFICIENT; DAILY LIFE ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; ECHO PLANAR IMAGING; FEMALE; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ACTIVITIES OF DAILY LIVING; AGED; ALZHEIMER DISEASE; ATHEROSCLEROSIS; CAROTID ARTERY DISEASES; CHOLINESTERASE INHIBITORS; FEMALE; GALANTAMINE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS;

EID: 63149164399     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200923030-00006     Document Type: Article

References (40)

1. Ritchie CW, Ames D, Clayton T, et al. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. Am J Geriatr Psychiatry 2004; 12: 358-69
2. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2004; (4): CD001747
3. Skoog I, Kalaria RN, Breteler MM. Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord 1999; 13 Suppl. 3: 106-14
4. Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283-90
5. Perry E, Ziabreva I, Perry R, et al. Absence of cholinergic deficits in pure vascular dementia. Neurology 2005; 64: 132-3
6. Johnston SC, O'Meara ES, Manolio TA, et al. Cognitive impairment and decline are associated with carotid artery disease in patients without clinically evident cerebrovascular disease. Ann Intern Med 2004; 140: 237-47
7. Komulainen P, Kivipelto M, Lakka TA, et al. Carotid intima-media thickness and cognitive function in elderly women: a population-based study. Neuroepidemiology 2007; 28: 207-13
8. Muller M, Grobbee DE, Aleman A, et al. Cardiovascular disease and cognitive performance in middle aged and elderly men. Atherosclerosis 2007; 190: 143-9
9. Silvestrini M, Gobbi B, Pascualetti P, et al. Carotid atherosclerosis and cognitive decline in patients with Alzheimer's disease. Neurobiol Aging. Epub 2007 Dec 10
10. Aguero-Torres H, Kivipelto M, von Strauss E. Rethinking the dementia diagnosis in a population-based study: what is Alzheimer's disease and what is vascular dementia? A study from the Kungsholmen project. Dement Geriatr Cogn Disord 2006; 22: 244-9
11. Grammas P, Yamada M, Zlokovic B. The cerebro-microvasculature: a key player in the pathogenesis of Alzheimer's disease. J Alzheimers Dis 2002; 4: 217-23
12. Humpel C, Marksteiner J. Cerebrovascular damage as a cause for Alzheimer's disease. Curr Neurovasc Res 2005; 2: 341-7
13. MacGowan SH, Wilcock GK, Scott M. Effect of gender and apolipoprotein E genotype on response to anti-cholinesterase therapy in Alzheimer's disease. Int J Geriatr Psychiatry 1998; 13: 625-30
14. Rigaud AS, Traykov L, Latour F, et al. Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease. Pharmacogenetics 2002; 12: 415-20
15. Wallin AK, Gustafson L, Sjogren M, et al. Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy. Dement Geriatr Cogn Disord 2004; 18: 197-206
16. Adler G, Brassen S, Chwalek K, et al. Prediction of treatment response to rivastigmine in Alzheimer's dementia. J Neurol Neurosurg Psychiatry 2004; 75: 292-4
17. Tanaka M, Namiki C, Thuy DH, et al. Prediction of psychiatric response to donepezil in patients with mild to moderate Alzheimer's disease. J Neurol Sci 2004; 225: 135-41
18. Csernansky JG, Wang L, Miller JP, et al. Neuroanatomical predictors of response to donepezil therapy in patients with dementia. Arch Neurol 2005; 62: 1718-22
19. Di Lazzaro V, Oliviero A, Pilato F, et al. Neurophysiological predictors of long term response to AchE inhibitors in AD patients. J Neurol Neurosurg Psychiatry 2005; 76: 1064-9
20. Visser PJ, Scheltens P, Pelgrim E, et al. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients. Dutch ENA-NL-01 Study Group. Dement Geriatr Cogn Disord 2005; 19: 126-33
21. McKhan G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA work group. Neurology 1984; 34: 939-44
22. Lobo A, Ezquerra J, Gomez Burgada F, et al. Cognitive mini-test (a simple practical test to detect intellectual changes in medical patients) [in Spanish]. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1979; 7: 189-202
23. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for staging of dementia. Br J Psychiatry 1982; 140: 566-72
24. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43: 250-60
25. Hachinski VC, Illif LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol 1975; 32: 623-37
26. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile change in the cerebral gray matter of elderly subjects. Br J Psychiatry 1968; 114: 797-811
27. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-64
28. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14
29. Gelinas I, Gauthier L, McIntire M, et al. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 1999; 53: 471-81
30. Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001; 32: 1318-22
31. Cummings JL, Schneider L, Tariot PN, et al. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry 2004; 161: 532-8
32. Bullock R, Erkinjuntti T, Lilienfeld S. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine. GAL-INT-6 Study Group. Dement Geriatr Cogn Disord 2004; 17: 29-34
33. Shimizu S, Hanyu H, Iwamoto K, et al. SPECT follow-up study of cerebral blood flow changes during donepezil therapy in patients with Alzheimer's disease. J Neuroimaging 2006; 16: 16-23
34. Mega MS, Dinov ID, Lee J, et al. Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2000; 12: 209-18
35. Nobili F, Koulibay M, Vitali P, et al. Brain perfusion followup in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. J Nucl Med 2002; 43: 983-90
36. Haywood WM, Mukaetova-Ladinska EB. Sex influences on cholinesterase inhibitor treatment in elderly individuals with Alzheimer's disease. Am J Geriatr Pharmacother 2006; 24: 273-86
37. Wang RJ, Bejar C, Weinstock M. Sex differences in the effect of rivastigmine on brain cholinesterase activity and cognitive function in rats. Neuropharmacology 2000; 39: 497-506
38. Wang RH, Weinstock M. Steroid hormones mediated sex difference in brain levels of tacrine and its hypothermic effect in the rat. Neuropharmacology 2001; 41: 887-94
39. Bär KJ, Boettger MK, Seidler N, et al. Influence of galantamine on vasomotor reactivity in Alzheimer's disease and vascular dementia due to cerebral microangiopathy. Stroke 2007; 38: 3186-92
40. Knopman D, Boland LL, Mosley T, et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001; 56: 42-8